|
1
|
Matz M, Coleman MP, Sant M, Chirlaque MD,
Visser O, Gore M and Allemani C; the CONCORD Working Group: The
histology of ovarian cancer: Worldwide distribution and
implications for international survival comparisons (CONCORD-2).
Gynecol Oncol. 144:405–413. 2017. View Article : Google Scholar
|
|
2
|
Lisio MA, Fu L, Goyeneche A, Gao ZH and
Telleria C: High-grade serous ovarian cancer: Basic sciences,
clinical and therapeutic standpoints. Int J Mol Sci. 20:9522019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mallen A, Soong TR, Townsend MK, Wenham
RM, Crum CP and Tworoger SS: Surgical prevention strategies in
ovarian cancer. Gynecol Oncol. 151:166–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Menon U, Karpinskyj C and Gentry-Maharaj
A: Ovarian cancer prevention and screening. Obstet Gynecol.
131:909–927. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Malley DM: New therapies for ovarian
cancer. J Natl Compr Canc Netw. 17:619–621. 2019.PubMed/NCBI
|
|
9
|
Zhang M, Cheng S, Jin Y, Zhao Y and Wang
Y: Roles of CA125 in diagnosis, prediction and oncogenesis of
ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021.
View Article : Google Scholar
|
|
10
|
Berridge MJ, Lipp P and Bootman MD: The
versatility and universality of calcium signalling. Nat Rev Mol
Cell Biol. 1:11–21. 2000. View Article : Google Scholar
|
|
11
|
Altamura C, Greco MR, Carratù MR, Cardone
RA and Desaphy JF: Emerging roles for ion channels in ovarian
cancer: Pathomechanisms and pharmacological treatment. Cancers
(Basel). 13. pp. 6682021, View Article : Google Scholar
|
|
12
|
Caravia L, Staicu CE, Radu BM, Condrat CE,
Crețoiu D, Bacalbașa N, Suciu N, Crețoiu SM and Voinea SC: Altered
organelle calcium transport in ovarian physiology and cancer.
Cancers (Basel). 12:22322020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monteith GR, McAndrew D, Faddy HM and
Roberts-Thomson SJ: Calcium and cancer: Targeting Ca2+ transport.
Nat Rev Cancer. 7:519–530. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McConkey DJ and Orrenius S: The role of
calcium in the regulation of apoptosis. Biochem Biophys Res Commun.
239:357–366. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prevarskaya N, Skryma R and Shuba Y:
Calcium in tumour metastasis: New roles for known actors. Nat Rev
Cancer. 11:609–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pulliam TL, Goli P, Awad D, Lin C,
Wilkenfeld SR and Frigo DE: Regulation and role of CAMKK2 in
prostate cancer. Nat Rev Urol. 19:367–380. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Venkatachalam K, Luo J and Montell C:
Evolutionarily conserved, multitasking TRP channels: Lessons from
worms and flies. Handb Exp Pharmacol. 223:937–962. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen JP, Wang J, Luan Y, Wang CX, Li WH,
Zhang JB, Sha D, Shen R, Cui YG, Zhang Z, et al: TRPM7 promotes the
metastatic process in human nasopharyngeal carcinoma. Cancer Lett.
356:483–490. 2015. View Article : Google Scholar
|
|
19
|
Chen X, Sooch G, Demaree IS, White FA and
Obukhov AG: Transient receptor potential canonical (TRPC) channels:
Then and now. Cells. 9:19832020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He B, Liu F, Ruan J, Li A, Chen J, Li R,
Shen J, Zheng D and Luo R: Silencing TRPC1 expression inhibits
invasion of CNE2 nasopharyngeal tumor cells. Oncol Rep.
27:1548–1554. 2012.PubMed/NCBI
|
|
21
|
Ong HL and Ambudkar IS: The dynamic
complexity of the TRPC1 channelosome. Channels (Austin). 5:424–431.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Zou J, Su J, Lu Y, Zhang J, Li L
and Yin F: Downregulation of transient receptor potential cation
channel, subfamily C, member 1 contributes to drug resistance and
high histological grade in ovarian cancer. Int J Oncol. 48:243–252.
2016. View Article : Google Scholar
|
|
23
|
Yang SL, Cao Q, Zhou KC, Feng YJ and Wang
YZ: Transient receptor potential channel C3 contributes to the
progression of human ovarian cancer. Oncogene. 28:1320–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu
J, Bast RC Jr, Yu Y and Feng Y: FSH enhances the proliferation of
ovarian cancer cells by activating transient receptor potential
channel C3. Endocr Relat Cancer. 20:415–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li S, Jiang K, Li J, Hao X, Chu W, Luo C,
Zhu Y, Xie R and Chen B: Estrogen enhances the proliferation and
migration of ovarian cancer cells by activating transient receptor
potential channel C3. J Ovarian Res. 13:202020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu EL, Zhou YX, Li J, Zhang DH and Liang
F: Long-chain non-coding RNA SNHG3 promotes the growth of ovarian
cancer cells by targeting miR-339-5p/TRPC3 axis. Onco Targets Ther.
13:10959–10971. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen Z, Gu L, Liu Y, Wang L, Zhu J, Tang
S, Wei X, Wang J, Zhang S, Wang X, et al: PLAA suppresses ovarian
cancer metastasis via METTL3-mediated m6A modification
of TRPC3 mRNA. Oncogene. 41:4145–4158. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Farfariello V, Gordienko DV, Mesilmany L,
Touil Y, Germain E, Fliniaux I, Desruelles E, Gkika D, Roudbaraki
M, Shapovalov G, et al: TRPC3 shapes the ER-mitochondria
Ca2+ transfer characterizing tumour-promoting
senescence. Nat Commun. 13:9562022. View Article : Google Scholar
|
|
29
|
Caterina MJ, Schumacher MA, Tominaga M,
Rosen TA, Levine JD and Julius D: The capsaicin receptor: A
heat-activated ion channel in the pain pathway. Nature.
389:816–824. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gunthorpe MJ, Benham CD, Randall A and
Davis JB: The diversity in the vanilloid (TRPV) receptor family of
ion channels. Trends Pharmacol Sci. 23:183–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Dong J, Tian W, Qiao S and Wang H:
Role of TRPV1 ion channel in cervical squamous cell carcinoma
genesis. Front Mol Biosci. 9:9802622022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lucido CT, Wynja E, Madeo M, Williamson
CS, Schwartz LE, Imblum BA, Drapkin R and Vermeer PD: Innervation
of cervical carcinoma is mediated by cancer-derived exosomes.
Gynecol Oncol. 154:228–235. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han GH, Chay DB, Nam S, Cho H, Chung JY
and Kim JH: Prognostic significance of transient receptor potential
vanilloid type 1 (TRPV1) and phosphatase and tension homolog (PTEN)
in epithelial ovarian cancer. Cancer Genomics Proteomics.
17:309–319. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YY, Lee KT, Lim MC and Choi JH: TRPV1
antagonist DWP05195 induces ER stress-dependent apoptosis through
the ROS-p38-CHOP pathway in human ovarian cancer cells. Cancers
(Basel). 12:17022020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Di Y, Xu T, Tian Y, Ma T, Qu D, Wang Y,
Lin Y, Bao D, Yu L, Liu S and Wang A: Ursolic acid protects against
cisplatin-induced ototoxicity by inhibiting oxidative stress and
TRPV1-mediated Ca2+-signaling. Int J Mol Med. 46:806–816. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Santoni G, Amantini C, Maggi F, Marinelli
O, Santoni M, Nabissi M and Morelli MB: The TRPV2 cation channels:
From urothelial cancer invasiveness to glioblastoma multiforme
interactome signature. Lab Invest. 100:186–198. 2020. View Article : Google Scholar
|
|
37
|
Liberati S, Morelli MB, Amantini C,
Farfariello V, Santoni M, Conti A, Nabissi M, Cascinu S and Santoni
G: Loss of TRPV2 homeostatic control of cell proliferation drives
tumor progression. Cells. 3:112–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fraguas-Sánchez AI, Fernández-Carballido
A, Delie F, Cohen M, Martin-Sabroso C, Mezzanzanica D, Figini M,
Satta A and Torres-Suárez AI: Enhancing ovarian cancer conventional
chemotherapy through the combination with cannabidiol loaded
microparticles. Eur J Pharm Biopharm. 154:246–258. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Griffiths C, Aikins J, Warshal D and
Ostrovsky O: Can cannabidiol affect the efficacy of chemotherapy
and epigenetic treatments in cancer? Biomolecules. 11:7662021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dutta B, Arya RK, Goswami R, Alharbi MO,
Sharma S and Rahaman SO: Role of macrophage TRPV4 in inflammation.
Lab Invest. 100:178–185. 2020. View Article : Google Scholar :
|
|
41
|
Wang K, Feng X, Zheng L, Chai Z, Yu J, You
X, Li X and Cheng X: TRPV4 is a prognostic biomarker that
correlates with the immunosuppressive microenvironment and
chemoresistance of anti-cancer drugs. Front Mol Biosci.
8:6905002021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang C, Xu C, Ma C, Zhang Q, Bu S, Zhang
DL, Yu L and Wang H: TRPs in ovarian serous cystadenocarcinoma: The
expression patterns, prognostic roles, and potential therapeutic
targets. Front Mol Biosci. 9:9154092022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu S, Huang S, Ding Y, Wang W, Wang A and
Lu Y: Transient receptor potential ion-channel subfamily V member
4: A potential target for cancer treatment. Cell Death Dis.
10:4972019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bödding M and Flockerzi V: Ca2+ dependence
of the Ca2+-selective TRPV6 channel. J Biol Chem. 279:36546–36552.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gees M, Colsoul B and Nilius B: The role
of transient receptor potential cation channels in Ca2+ signaling.
Cold Spring Harb Perspect Biol. 2:a0039622010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lehen'kyi V, Flourakis M, Skryma R and
Prevarskaya N: TRPV6 channel controls prostate cancer cell
proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene.
26:7380–7385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu X, Li N, Wang Y, Yu J and Mi J: Calcium
channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer
Lett. 519:150–160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xue H, Wang Y, MacCormack TJ, Lutes T,
Rice C, Davey M, Dugourd D, Ilenchuk TT and Stewart JM: Inhibition
of transient receptor potential vanilloid 6 channel, elevated in
human ovarian cancers, reduces tumour growth in a xenograft model.
J Cancer. 9:3196–3207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang Y, Gou H, Zhu J, Tian S and Yu L:
Lidocaine inhibits the invasion and migration of TRPV6-expressing
cancer cells by TRPV6 downregulation. Oncol Lett. 12:1164–1170.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang X, Li G, Zhang Y, Li L, Qiu L, Qian
Z, Zhou S, Wang X, Li Q and Zhang H: Pan-cancer analysis reveals
genomic and clinical characteristics of TRPV channel-related genes.
Front Oncol. 12:8131002022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tong Q, Zhang W, Conrad K, Mostoller K,
Cheung JY, Peterson BZ and Miller BA: Regulation of the transient
receptor potential channel TRPM2 by the Ca2+ sensor calmodulin. J
Biol Chem. 281:9076–9085. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Orfanelli U, Wenke AK, Doglioni C, Russo
V, Bosserhoff AK and Lavorgna G: Identification of novel sense and
antisense transcription at the TRPM2 locus in cancer. Cell Res.
18:1128–1140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ding Y, Tan X, Abasi A, Dai Y, Wu R, Zhang
T, Li K, Yan M and Huang X: LncRNA TRPM2-AS promotes ovarian cancer
progression and cisplatin resistance by sponging miR-138-5pto
release SDC3 mRNA. Aging (Albany NY). 13:6832–6848. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dai W, Bai Y, Hebda L, Zhong X, Liu J, Kao
J and Duan C: Calcium deficiency-induced and TRP channel-regulated
IGF1R-PI3K-Akt signaling regulates abnormal epithelial cell
proliferation. Cell Death Differ. 21:568–581. 2014. View Article : Google Scholar :
|
|
55
|
Abed E, Martineau C and Moreau R: Role of
melastatin transient receptor potential 7 channels in the
osteoblastic differentiation of murine MC3T3 cells. Calcif Tissue
Int. 88:246–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yee NS, Kazi AA and Yee RK: Cellular and
developmental biology of TRPM7 channel-kinase: Implicated roles in
cancer. Cells. 3:751–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang J, Xiao L, Luo CH, Zhou H, Hu J, Tang
YX, Fang KN and Zhang Y: Overexpression of TRPM7 is associated with
poor prognosis in human ovarian carcinoma. Asian Pac J Cancer Prev.
15:3955–3958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang J, Liao QJ, Zhang Y, Zhou H, Luo CH,
Tang J, Wang Y, Tang Y, Zhao M, Zhao XH, et al: TRPM7 is required
for ovarian cancer cell growth, migration and invasion. Biochem
Biophys Res Commun. 454:547–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu L, Wu N, Wang Y, Zhang X, Xia B, Tang
J, Cai J, Zhao Z, Liao Q and Wang J: TRPM7 promotes the
epithelial-mesenchymal transition in ovarian cancer through the
calcium-related PI3K/AKT oncogenic signaling. J Exp Clin Cancer
Res. 38:1062019. View Article : Google Scholar
|
|
60
|
Catterall WA: Voltage-gated calcium
channels. Cold Spring Harb Perspect Biol. 3:a0039472011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li W, Zhang SL, Wang N, Zhang BB and Li M:
Blockade of T-type Ca(2+) channels inhibits human ovarian cancer
cell proliferation. Cancer Invest. 29:339–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jang SJ, Choi HW, Choi DL, Cho S, Rim HK,
Choi HE, Kim KS, Huang M, Rhim H, Lee KT and Lee JY: In vitro
cytotoxicity on human ovarian cancer cells by T-type calcium
channel blockers. Bioorg Med Chem Lett. 23:6656–6662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dziegielewska B, Casarez EV, Yang WZ, Gray
LS, Dziegielewski J and Slack-Davis JK: T-type Ca2+ channel
inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer
Ther. 15:460–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mir R, Stanzani E, Martinez-Soler F,
Villanueva A, Vidal A, Condom E, Ponce J, Gil J, Tortosa A and
Giménez-Bonafé P: YM155 sensitizes ovarian cancer cells to
cisplatin inducing apoptosis and tumor regression. Gynecol Oncol.
132:211–220. 2014. View Article : Google Scholar
|
|
65
|
Fornaro L, Vivaldi C, Lin D, Xue H,
Falcone A, Wang Y, Crea F and Bootman MD: Prognostic relevance of a
T-type calcium channels gene signature in solid tumours: A
correlation ready for clinical validation. PLoS One.
12:e01828182017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mertens-Walker I, Bolitho C, Baxter RC and
Marsh DJ: Gonadotropin-induced ovarian cancer cell migration and
proliferation require extracellular signal-regulated kinase 1/2
activation regulated by calcium and protein kinase C{delta}. Endocr
Relat Cancer. 17:335–349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim EK, Ha JM, Kim YW, Jin SY, Ha HK and
Bae SS: Inhibitory role of polyunsaturated fatty acids on
lysophosphatidic acid-induced cancer cell migration and adhesion.
FEBS Lett. 588:2971–2977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lee H, Kim JW, Kim DK, Choi DK, Lee S, Yu
JH, Kwon OB, Lee J, Lee DS, Kim JH and Min SH: Calcium channels as
novel therapeutic targets for ovarian cancer stem cells. Int J Mol
Sci. 21:23272020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lee H, Kwon OB, Lee JE, Jeon YH, Lee DS,
Min SH and Kim JW: Repositioning trimebutine maleate as a cancer
treatment targeting ovarian cancer stem cells. Cells. 10:9182021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chang X and Dong Y: CACNA1C is a
prognostic predictor for patients with ovarian cancer. J Ovarian
Res. 14:882021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Niemeyer BA: Changing calcium: CRAC
channel (STIM and Orai) expression, splicing, and posttranslational
modifiers. Am J Physiol Cell Physiol. 310:C701–C709. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Khan HY, Mazahir I, Reddy S, Fazili F and
Azmi A: Roles of CRAC channel in cancer: Implications for
therapeutic development. Expert Rev Precis Med Drug Dev. 5:371–382.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Abdelazeem KNM, Droppova B, Sukkar B,
Al-Maghout T, Pelzl L, Zacharopoulou N, Ali Hassan NH, Abdel-Fattah
KI, Stournaras C and Lang F: Upregulation of Orai1 and STIM1
expression as well as store-operated Ca2+ entry in ovary
carcinoma cells by placental growth factor. Biochem Biophys Res
Commun. 512:467–472. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schmidt S, Liu G, Liu G, Yang W, Honisch
S, Pantelakos S, Stournaras C, Hönig A and Lang F: Enhanced Orai1
and STIM1 expression as well as store operated Ca2+ entry in
therapy resistant ovary carcinoma cells. Oncotarget. 5:4799–4810.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zahid M, Beseler CL, Hall JB, LeVan T,
Cavalieri EL and Rogan EG: Unbalanced estrogen metabolism in
ovarian cancer. Int J Cancer. 134:2414–2423. 2014. View Article : Google Scholar :
|
|
76
|
Lv X, Miao C, Liu M, Wang X, Wang L and
Wang D: 17β-Estradiol via Orai1 activates calcium mobilization to
induce cell proliferation in epithelial ovarian cancer. J Biochem
Mol Toxicol. 34:e226032020. View Article : Google Scholar
|
|
77
|
Ouadid-Ahidouch H, Roudbaraki M, Delcourt
P, Ahidouch A, Joury N and Prevarskaya N: Functional and molecular
identification of intermediate-conductance Ca(2+)-activated K(+)
channels in breast cancer cells: Association with cell cycle
progression. Am J Physiol Cell Physiol. 287:C125–C134. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kunzelmann K: Ion channels and cancer. J
Membr Biol. 205:159–173. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Han X, Xi L, Wang H, Huang X, Ma X, Han Z,
Wu P, Ma X, Lu Y, Wang G, et al: The potassium ion channel opener
NS1619 inhibits proliferation and induces apoptosis in A2780
ovarian cancer cells. Biochem Biophys Res Commun. 375:205–209.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Berkefeld H, Sailer CA, Bildl W, Rohde V,
Thumfart JO, Eble S, Klugbauer N, Reisinger E, Bischofberger J,
Oliver D, et al: BKCa-Cav channel complexes mediate rapid and
localized Ca2+-activated K+ signaling. Science. 314:615–620. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Oeggerli M, Tian Y, Ruiz C, Wijker B,
Sauter G, Obermann E, Güth U, Zlobec I, Sausbier M, Kunzelmann K
and Bubendorf L: Role of KCNMA1 in breast cancer. PLoS One.
7:e416642012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Samuel P, Pink RC, Caley DP, Currie JM,
Brooks SA and Carter DR: Over-expression of miR-31 or loss of
KCNMA1 leads to increased cisplatin resistance in ovarian cancer
cells. Tumour Biol. 37:2565–2573. 2016. View Article : Google Scholar
|
|
83
|
Lundstrom K: Structural genomics of GPCRs.
Trends Biotechnol. 23:103–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Oldham WM and Hamm HE: Heterotrimeric G
protein activation by G-protein-coupled receptors. Nat Rev Mol Cell
Biol. 9:60–71. 2008. View Article : Google Scholar
|
|
85
|
Tu CL, Oda Y, Komuves L and Bikle DD: The
role of the calcium-sensing receptor in epidermal differentiation.
Cell Calcium. 35:265–273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rodland KD: The role of the
calcium-sensing receptor in cancer. Cell Calcium. 35:291–295. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yan S, Yuan C, Yang Q, Li X, Yang N, Liu
X, Dong R, Zhang X, Yuan Z, Zhang N and Kong B: A genetic
polymorphism (rs17251221) in the calcium-sensing receptor is
associated with ovarian cancer susceptibility. Oncol Rep.
34:2151–2155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Park KS, Kim MK, Im DS and Bae YS: Effect
of lysophosphatidylglycerol on several signaling molecules in
OVCAR-3 human ovarian cancer cells: Involvement of pertussis
toxin-sensitive G-protein coupled receptor. Biochem Pharmacol.
73:675–681. 2007. View Article : Google Scholar
|
|
89
|
Smith HO, Arias-Pulido H, Kuo DY, Howard
T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE and
Prossnitz ER: GPR30 predicts poor survival for ovarian cancer.
Gynecol Oncol. 114:465–471. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yan Y, Liu H, Wen H, Jiang X, Cao X, Zhang
G and Liu G: The novel estrogen receptor GPER regulates the
migration and invasion of ovarian cancer cells. Mol Cell Biochem.
378:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Heublein S, Mayr D, Friese K,
Jarrin-Franco MC, Lenhard M, Mayerhofer A and Jeschke U: The
G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian
granulosa cell tumors. Int J Mol Sci. 15:15161–15172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yan Y, Jiang X, Zhao Y, Wen H and Liu G:
Role of GPER on proliferation, migration and invasion in
ligand-independent manner in human ovarian cancer cell line SKOV3.
Cell Biochem Funct. 33:552–559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ignatov T, Modl S, Thulig M, Weißenborn C,
Treeck O, Ortmann O, Zenclussen A, Costa SD, Kalinski T and Ignatov
A: GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian
Res. 6:512013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Predescu DV, Crețoiu SM, Crețoiu D,
Pavelescu LA, Suciu N, Radu BM and Voinea SC: G protein-coupled
receptors (GPCRs)-mediated calcium signaling in ovarian cancer:
Focus on GPCRs activated by neurotransmitters and
inflammation-associated molecules. Int J Mol Sci. 20:55682019.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Xue D, Chen W and Neamati N: Discovery,
structure-activity relationship study and biological evaluation of
2-thioureidothiophene-3-carboxylates as a novel class of C-X-C
chemokine receptor 2 (CXCR2) antagonists. Eur J Med Chem.
204:1123872020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Seo MD, Velamakanni S, Ishiyama N,
Stathopulos PB, Rossi AM, Khan SA, Dale P, Li C, Ames JB, Ikura M
and Taylor CW: Structural and functional conservation of key
domains in InsP3 and ryanodine receptors. Nature. 483:108–112.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Vermassen E, Parys JB and Mauger JP:
Subcellular distribution of the inositol 1,4,5-trisphosphate
receptors: Functional relevance and molecular determinants. Biol
Cell. 96:3–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Giannini G, Clementi E, Ceci R, Marziali G
and Sorrentino V: Expression of a ryanodine receptor-Ca2+ channel
that is regulated by TGF-beta. Science. 257:91–94. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Santulli G, Nakashima R, Yuan Q and Marks
AR: Intracellular calcium release channels: An update. J Physiol.
595:3041–3051. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ando H, Hirose M and Mikoshiba K: Aberrant
IP3 receptor activities revealed by comprehensive
analysis of pathological mutations causing spinocerebellar ataxia
29. Proc Natl Acad Sci USA. 115:12259–12264. 2018. View Article : Google Scholar
|
|
101
|
Díaz-Muñoz M, de la Rosa Santander P,
Juárez-Espinosa AB, Arellano RO and Morales-Tlalpan V: Granulosa
cells express three inositol 1,4,5-trisphosphate receptor isoforms:
Cytoplasmic and nuclear Ca2+ mobilization. Reprod Biol Endocrinol.
6:602008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hanson CJ, Bootman MD and Roderick HL:
Cell signalling: IP3 receptors channel calcium into cell death.
Curr Biol. 14:R933–R935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Lahiri S, Roy A, Li J, Mokashi A and Baby
SM: Ca2+ responses to hypoxia are mediated by IP3-R on Ca2+ store
depletion. Adv Exp Med Biol. 536:25–32. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lencesova L, Vlcek M, Krizanova O and
Hudecova S: Hypoxic conditions increases H2S-induced ER stress in
A2870 cells. Mol Cell Biochem. 414:67–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Yu Y, Xie Q, Liu W, Guo Y, Xu N, Xu L, Liu
S, Li S, Xu Y and Sun L: Increased intracellular Ca2+
decreases cisplatin resistance by regulating iNOS expression in
human ovarian cancer cells. Biomed Pharmacother. 86:8–15. 2017.
View Article : Google Scholar
|
|
106
|
Xie Q, Xu Y, Gao W, Zhang Y, Su J, Liu Y,
Guo Y, Dou M, Hu K and Sun L: TAT-fused IP3R-derived peptide
enhances cisplatin sensitivity of ovarian cancer cells by
increasing ER Ca2+ release. Int J Mol Med. 41:809–817. 2018.
|
|
107
|
Rezuchova I, Hudecova S, Soltysova A,
Matuskova M, Durinikova E, Chovancova B, Zuzcak M, Cihova M,
Burikova M, Penesova A, et al: Type 3 inositol 1,4,5-trisphosphate
receptor has antiapoptotic and proliferative role in cancer cells.
Cell Death Dis. 10:1862019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Sneyers F, Rosa N and Bultynck G: Type 3
IP3 receptors driving oncogenesis. Cell Calcium.
86:1021412020. View Article : Google Scholar
|
|
109
|
Xue Y, Morris JL, Yang K, Fu Z, Zhu X,
Johnson F, Meehan B, Witkowski L, Yasmeen A, Golenar T, et al:
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by
restricting IP3R3-mediated Ca2+ flux to mitochondria.
Nat Commun. 12:54042021. View Article : Google Scholar
|
|
110
|
Kucukkaya B, Erdag D, Akbas F and
Yalcintepe L: The effect of iron on the expression levels of
calcium related gene in cisplatin resistant epithelial ovarian
cancer cells. Explor Target Antitumor Ther. 2:309–322.
2021.PubMed/NCBI
|
|
111
|
Meissner G: The structural basis of
ryanodine receptor ion channel function. J Gen Physiol.
149:1065–1089. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Mariot P, Prevarskaya N, Roudbaraki MM, Le
Bourhis X, Van Coppenolle F, Vanoverberghe K and Skryma R: Evidence
of functional ryanodine receptor involved in apoptosis of prostate
cancer (LNCaP) cells. Prostate. 43:205–214. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu
H, Liu P, Hao X, Zhang W and Chen K: Functional SNP in the
microRNA-367 binding site in the 3'UTR of the calcium channel
ryanodine receptor gene 3 (RYR3) affects breast cancer risk and
calcification. Proc Natl Acad Sci USA. 108:13653–13658. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Schmitt K, Molfenter B, Laureano NK, Tawk
B, Bieg M, Hostench XP, Weichenhan D, Ullrich ND, Shang V, Richter
D, et al: Somatic mutations and promotor methylation of the
ryanodine receptor 2 is a common event in the pathogenesis of head
and neck cancer. Int J Cancer. 145:3299–3310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Andruska ND, Zheng X, Yang X, Mao C,
Cherian MM, Mahapatra L, Helferich WG and Shapiro DJ: Estrogen
receptor α inhibitor activates the unfolded protein response,
blocks protein synthesis, and induces tumor regression. Proc Natl
Acad Sci USA. 112:4737–4742. 2015. View Article : Google Scholar
|
|
116
|
Zheng X, Andruska N, Lambrecht MJ, He S,
Parissenti A, Hergenrother PJ, Nelson ER and Shapiro DJ: Targeting
multidrug-resistant ovarian cancer through estrogen receptor α
dependent ATP depletion caused by hyperactivation of the unfolded
protein response. Oncotarget. 9:14741–14753. 2018. View Article : Google Scholar
|
|
117
|
Williams CJ and Erickson GF: Morphology
and Physiology of the Ovary. Endotext. Feingold KR, Anawalt B,
Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya
K, Dungan K, Hofland J, et al: South Dartmouth, MA: MDText.com,
Inc.; 2000
|
|
118
|
Cui C, Merritt R, Fu L and Pan Z:
Targeting calcium signaling in cancer therapy. Acta Pharm Sin B.
7:3–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Seo JA, Kim B, Dhanasekaran DN, Tsang BK
and Song YS: Curcumin induces apoptosis by inhibiting
sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer
cells. Cancer Lett. 371:30–37. 2016. View Article : Google Scholar
|
|
121
|
Sun Z, Zhang H, Wang X, Wang QC, Zhang C,
Wang JQ, Wang YH, An CQ, Yang KY, Wang Y, et al: TMCO1 is essential
for ovarian follicle development by regulating ER Ca2+
store of granulosa cells. Cell Death Differ. 25:1686–1701. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Huang N, Yu Y and Qiao J: Dual role for
the unfolded protein response in the ovary: Adaption and apoptosis.
Protein Cell. 8:14–24. 2017. View Article : Google Scholar :
|
|
123
|
Peluso JJ: Basic fibroblast growth factor
(bFGF) regulation of the plasma membrane calcium ATPase (PMCA) as
part of an anti-apoptotic mechanism of action. Biochem Pharmacol.
66:1363–1369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Solár P and Sytkowski AJ: Differentially
expressed genes associated with cisplatin resistance in human
ovarian adenocarcinoma cell line A2780. Cancer Lett. 309:11–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kucukkaya B, Basoglu H, Erdag D, Akbas F,
Susgun S and Yalcintepe L: Calcium homeostasis in cisplatin
resistant epithelial ovarian cancer. Gen Physiol Biophys.
38:353–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Baughman JM, Perocchi F, Girgis HS,
Plovanich M, Belcher-Timme CA, Sancak Y, Bao XR, Strittmatter L,
Goldberger O, Bogorad RL, et al: Integrative genomics identifies
MCU as an essential component of the mitochondrial calcium
uniporter. Nature. 476:341–345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Marchi S and Pinton P: The mitochondrial
calcium uniporter complex: Molecular components, structure and
physiopathological implications. J Physiol. 592:829–839. 2014.
View Article : Google Scholar :
|
|
128
|
Patron M, Checchetto V, Raffaello A,
Teardo E, Vecellio Reane D, Mantoan M, Granatiero V, Szabò I, De
Stefani D and Rizzuto R: MICU1 and MICU2 finely tune the
mitochondrial Ca2+ uniporter by exerting opposite effects on MCU
activity. Mol Cell. 53:726–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Denton RM: Regulation of mitochondrial
dehydrogenases by calcium ions. Biochim Biophys Acta.
1787:1309–1316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Chakraborty PK, Mustafi SB, Xiong X,
Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M,
Mannel R, et al: MICU1 drives glycolysis and chemoresistance in
ovarian cancer. Nat Commun. 8:146342017. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Hempel N and Trebak M: Crosstalk between
calcium and reactive oxygen species signaling in cancer. Cell
Calcium. 63:70–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Porporato PE, Payen VL, Pérez-Escuredo J,
De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T,
Bouzin C, et al: A mitochondrial switch promotes tumor metastasis.
Cell Rep. 8:754–766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Moloney JN and Cotter TG: ROS signalling
in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018.
View Article : Google Scholar
|
|
134
|
Ham J, Lim W, Kim K, Heo YM, Ryu SM, Lee
D, Kim JJ and Song G: Gentisyl alcohol inhibits proliferation and
induces apoptosis via mitochondrial dysfunction and regulation of
MAPK and PI3K/AKT pathways in epithelial ovarian cancer cells. Mar
Drugs. 17:3312019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Bae H, Park S, Ham J, Song J, Hong T, Choi
JH, Song G and Lim W: ER-mitochondria calcium flux by β-sitosterol
promotes cell death in ovarian cancer. Antioxidants (Basel).
10:15832021. View Article : Google Scholar
|
|
136
|
Bae H, Park S, Yang C, Song G and Lim W:
Disruption of endoplasmic reticulum and ROS production in human
ovarian cancer by campesterol. Antioxidants (Basel). 10:3792021.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Bae H, Song G and Lim W: Stigmasterol
causes ovarian cancer cell apoptosis by inducing endoplasmic
reticulum and mitochondrial dysfunction. Pharmaceutics. 12:4882020.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bae H, Lee JY, Song J, Song G and Lim W:
Osthole interacts with an ER-mitochondria axis and facilitates
tumor suppression in ovarian cancer. J Cell Physiol. 236:1025–1042.
2021. View Article : Google Scholar
|
|
139
|
Bae H, Lee JY, Song G and Lim W:
Fucosterol suppresses the progression of human ovarian cancer by
inducing mitochondrial dysfunction and endoplasmic reticulum
stress. Mar Drugs. 18:2612020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bae H, Song G, Lee JY, Hong T, Chang MJ
and Lim W: Laminarin-derived from brown algae suppresses the growth
of ovarian cancer cells via mitochondrial dysfunction and ER
stress. Mar Drugs. 18:1522020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lim W, An Y, Yang C, Bazer FW and Song G:
Chrysophanol induces cell death and inhibits invasiveness via
mitochondrial calcium overload in ovarian cancer cells. J Cell
Biochem. 119:10216–10227. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Lim W, Ryu S, Bazer FW, Kim SM and Song G:
Chrysin attenuates progression of ovarian cancer cells by
regulating signaling cascades and mitochondrial dysfunction. J Cell
Physiol. 233:3129–3140. 2018. View Article : Google Scholar
|
|
143
|
Rogalska A, Szula E, Gajek A, Marczak A
and Jóźwiak Z: Activation of apoptotic pathway in normal, cancer
ovarian cells by epothilone B. Environ Toxicol Pharmacol.
36:600–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Giorgi C, Baldassari F, Bononi A, Bonora
M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Rimessi A,
Suski JM, et al: Mitochondrial Ca(2+) and apoptosis. Cell Calcium.
52:36–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Honrath B, Metz I, Bendridi N, Rieusset J,
Culmsee C and Dolga AM: Glucose-regulated protein 75 determines
ER-mitochondrial coupling and sensitivity to oxidative stress in
neuronal cells. Cell Death Discov. 3:170762017. View Article : Google Scholar
|
|
146
|
Ma L, Wang H, Wang C, Su J, Xie Q, Xu L,
Yu Y, Liu S, Li S, Xu Y and Li Z: Failure of elevating calcium
induces oxidative stress tolerance and imparts cisplatin resistance
in ovarian cancer cells. Aging Dis. 7:254–266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, Yu
Y, Li S and Xu Y: Bcl-2 overexpression reduces cisplatin
cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3
cells. Oncol Rep. 39:985–992. 2018.
|
|
148
|
Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X,
Yu C, Jiang X, Xu Y and Sun L: ABT737 reverses cisplatin resistance
by regulating ER-mitochondria Ca2+ signal transduction in human
ovarian cancer cells. Int J Oncol. 49:2507–2519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Li J, Qi F, Su H, Zhang C, Zhang Q, Chen
Y, Chen P, Su L, Chen Y, Yang Y, et al: GRP75-faciliated
mitochondria-associated ER membrane (MAM) integrity controls
cisplatin-resistance in ovarian cancer patients. Int J Biol Sci.
18:2914–2931. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Li L, Zeng S, Guo L, Huang P, Xi J, Feng
J, Li Q, Li Y, Xiao X, Yan R and Zhang J: Long noncoding RNA RMRP
contributes to paclitaxel sensitivity of ovarian cancer by
regulating miR-580-3p/MICU1 signaling. J Oncol.
2022:83019412022.PubMed/NCBI
|
|
151
|
Bresnick AR, Weber DJ and Zimmer DB: S100
proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zimmer DB, Eubanks JO, Ramakrishnan D and
Criscitiello MF: Evolution of the S100 family of calcium sensor
proteins. Cell Calcium. 53:170–179. 2013. View Article : Google Scholar
|
|
153
|
Bai Y, Li LD, Li J and Lu X: Prognostic
values of S100 family members in ovarian cancer patients. BMC
Cancer. 18:12562018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Hua X, Zhang H, Jia J, Chen S, Sun Y and
Zhu X: Roles of S100 family members in drug resistance in tumors:
Status and prospects. Biomed Pharmacother. 127:1101562020.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H
and Cui Z: S100A1 promotes cell proliferation and migration and is
associated with lymph node metastasis in ovarian cancer. Discov
Med. 23:235–245. 2017.PubMed/NCBI
|
|
156
|
Buckley NE, D'Costa Z, Kaminska M and
Mullan PB: S100A2 is a BRCA1/p63 coregulated tumour suppressor gene
with roles in the regulation of mutant p53 stability. Cell Death
Dis. 5:e10702014. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Kikuchi N, Horiuchi A, Osada R, Imai T,
Wang C, Chen X and Konishi I: Nuclear expression of S100A4 is
associated with aggressive behavior of epithelial ovarian
carcinoma: An important autocrine/paracrine factor in tumor
progression. Cancer Sci. 97:1061–1069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Horiuchi A, Hayashi T, Kikuchi N, Hayashi
A, Fuseya C, Shiozawa T and Konishi I: Hypoxia upregulates ovarian
cancer invasiveness via the binding of HIF-1α to a hypoxia-induced,
methylation-free hypoxia response element of S100A4 gene. Int J
Cancer. 131:1755–1767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yan W, Chen J, Chen Z and Chen H:
Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing
epithelial-mesenchymal transition in human ovarian cancer. Am J
Cancer Res. 6:260–269. 2016.PubMed/NCBI
|
|
160
|
Link T, Kuhlmann JD, Kobelt D, Herrmann P,
Vassileva YD, Kramer M, Frank K, Göckenjan M, Wimberger P and Stein
U: Clinical relevance of circulating MACC1 and S100A4 transcripts
for ovarian cancer. Mol Oncol. 13:1268–1279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Deo AN, Thorat R, Dhadve AC, De A, Rekhi B
and Ray P: IGF1R-α6 integrin-S100A4 network governs the
organ-specific metastasis of chemoresistant epithelial ovarian
cancer cells. Biochim Biophys Acta Mol Basis Dis. 1868:1662822022.
View Article : Google Scholar
|
|
162
|
Schäfer BW, Fritschy JM, Murmann P,
Troxler H, Durussel I, Heizmann CW and Cox JA: Brain S100A5 is a
novel calcium-, zinc-, and copper ion-binding protein of the
EF-hand superfamily. J Biol Chem. 275:30623–30630. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wei BR, Hoover SB, Ross MM, Zhou W, Meani
F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quiñones OA,
et al: Serum S100A6 concentration predicts peritoneal tumor burden
in mice with epithelial ovarian cancer and is associated with
advanced stage in patients. PLoS One. 4:e76702009. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Lin M, Xia B, Qin L, Chen H and Lou G:
S100A7 regulates ovarian cancer cell metastasis and chemoresistance
through MAPK signaling and is targeted by miR-330-5p. DNA Cell
Biol. 37:491–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Nymoen DA, Hetland Falkenthal TE, Holth A,
Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC and Davidson B:
Expression and clinical role of chemoresponse-associated genes in
ovarian serous carcinoma. Gynecol Oncol. 139:30–39. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Lokman NA, Pyragius CE, Ruszkiewicz A,
Oehler MK and Ricciardelli C: Annexin A2 and S100A10 are
independent predictors of serous ovarian cancer outcome. Transl
Res. 171:83–95.e1-e2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Wang L, Yan W, Li X, Liu Z, Tian T, Chen
T, Zou L and Cui Z: S100A10 silencing suppresses proliferation,
migration and invasion of ovarian cancer cells and enhances
sensitivity to carboplatin. J Ovarian Res. 12:1132019. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Xuan L, Sun Z, Wang J and Gao S: lncRNA
SNHG8 promotes ovarian cancer progression through serving as sponge
for miR-1270 to regulate S100A11 expression. J Gene Med.
e33152021.
|
|
169
|
Li W, Cui Z, Kong Y, Liu X and Wang X:
Serum levels of S100A11 and MMP-9 in patients with epithelial
ovarian cancer and their clinical significance. Biomed Res Int.
2021:73412472021.PubMed/NCBI
|
|
170
|
Qian J, Ding F, Luo A, Liu Z and Cui Z:
Overexpression of S100A14 in human serous ovarian carcinoma. Oncol
Lett. 11:1113–1119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Sturchler E, Cox JA, Durussel I, Weibel M
and Heizmann CW: S100A16, a novel calcium-binding protein of the
EF-hand superfamily. J Biol Chem. 281:38905–38917. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Yang T, Cheng J, Yang Y, Qi W, Zhao Y,
Long H, Xie R and Zhu B: S100B mediates stemness of ovarian cancer
stem-like cells through inhibiting p53. Stem Cells. 35:325–336.
2017. View Article : Google Scholar
|
|
173
|
Yang T, Cheng J, You J, Yan B, Liu H and
Li F: S100B promotes chemoresistance in ovarian cancer stem cells
by regulating p53. Oncol Rep. 40:1574–1582. 2018.PubMed/NCBI
|
|
174
|
Wang X, Tian T, Li X, Zhao M, Lou Y, Qian
J, Liu Z, Chen H and Cui Z: High expression of S100P is associated
with unfavorable prognosis and tumor progression in patients with
epithelial ovarian cancer. Am J Cancer Res. 5:2409–2421.
2015.PubMed/NCBI
|
|
175
|
Wang Q, He Z, Gao J, Hu S, Huang M, Liu M,
Zheng J and Tang H: S100P sensitizes ovarian cancer cells to
carboplatin and paclitaxel in vitro. Cancer Lett. 272:277–284.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Ma N, Zhu L, Yang L, Cui Y and Zhan Y:
Prognostic values of S100 family mRNA expression in ovarian cancer.
Cancer Biomark. 25:67–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Wu B, Yu C, Zhou B, Huang T, Gao L, Liu T
and Yang X: Overexpression of TROP2 promotes proliferation and
invasion of ovarian cancer cells. Exp Ther Med. 14:1947–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Dai S, Venturini E, Yadav S, Lin X, Clapp
D, Steckiewicz M, Gocher-Demske AM, Hardie DG and Edelman AM:
Calcium/calmodulin-dependent protein kinase kinase 2 mediates
pleiotropic effects of epidermal growth factor in cancer cells.
Biochim Biophys Acta Mol Cell Res. 1869:1192522022. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Chen LL, Xia LY, Zhang JP, Wang Y, Chen
JY, Guo C and Xu WH: Saikosaponin D alleviates cancer cachexia by
directly inhibiting STAT3. Phytother Res. 37:809–819. 2023.
View Article : Google Scholar
|
|
180
|
Laski J, Singha B, Wang X, Valdés YR,
Collins O and Shepherd TG: Activated CAMKKβ-AMPK signaling promotes
autophagy in a spheroid model of ovarian tumour metastasis. J
Ovarian Res. 13:582020. View Article : Google Scholar
|
|
181
|
Chen Z, Sun X, Xia Z, Wang J, Guo N and
Zhang Y: CaMKK2 promotes the progression of ovarian carcinoma
through the PI3K/PDK1/Akt axis. Comput Math Methods Med.
2022:71879402022.PubMed/NCBI
|
|
182
|
Tsuyoshi H, Wong VKW, Han Y, Orisaka M,
Yoshida Y and Tsang BK: Saikosaponin-d, a calcium mobilizing agent,
sensitizes chemoresistant ovarian cancer cells to cisplatin-induced
apoptosis by facilitating mitochondrial fission and G2/M arrest.
Oncotarget. 8:99825–99840. 2017. View Article : Google Scholar : PubMed/NCBI
|
